Literature DB >> 19380295

Genetic alterations in chronic lymphocytic leukaemia.

Llorenç Coll-Mulet1, Joan Gil.   

Abstract

Chronic lymphocytic leukaemia (CLL), the commonest form of leukaemia in adults in Western countries, is a genetically heterogeneous disease. The most frequent genetic alterations are deletions in 13q14, 17p13 (TP53) and 11q22-q23 (ATM), and trisomy of chromosome 12. Furthermore, additional alterations have been described. The most relevant techniques used for detection of genetic alterations in CLL include comparative genomic hybridisation (CGH) and fluorescence in situ hybridisation (FISH). Recently, PCR-based techniques, such as multiplex ligation- dependent probe amplification (MLPA), have been used to detect genetic alterations in CLL. This review summarises the genetic alterations described in CLL and the techniques used for their detection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380295     DOI: 10.1007/s12094-009-0340-z

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  62 in total

1.  Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia.

Authors:  G Tobin; A Skogsberg; U Thunberg; A Laurell; A Aleskog; M Merup; C Sundström; G Roos; K Nilsson; R Rosenquist
Journal:  Leukemia       Date:  2005-05       Impact factor: 11.528

2.  Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation.

Authors:  Hannah C Rudenko; Monica Else; Claire Dearden; Vasantha Brito-Babapulle; Chris Jones; Tim Dexter; Kerry Fenwick; Alan Mackay; Alan Ashworth; Estella Matutes; David Gonzalez; Daniel Catovsky; Gareth J Morgan
Journal:  Leuk Lymphoma       Date:  2008-10

3.  A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.

Authors:  Maria Chiara Di Bernardo; Dalemari Crowther-Swanepoel; Peter Broderick; Emily Webb; Gabrielle Sellick; Ruth Wild; Kate Sullivan; Jayaram Vijayakrishnan; Yufei Wang; Alan M Pittman; Nicola J Sunter; Andrew G Hall; Martin J S Dyer; Estella Matutes; Claire Dearden; Tryfonia Mainou-Fowler; Graham H Jackson; Geoffrey Summerfield; Robert J Harris; Andrew R Pettitt; Peter Hillmen; David J Allsup; James R Bailey; Guy Pratt; Chris Pepper; Chris Fegan; James M Allan; Daniel Catovsky; Richard S Houlston
Journal:  Nat Genet       Date:  2008-08-31       Impact factor: 38.330

4.  p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis.

Authors:  D Lens; M J Dyer; J M Garcia-Marco; P J De Schouwer; R A Hamoudi; D Jones; N Farahat; E Matutes; D Catovsky
Journal:  Br J Haematol       Date:  1997-12       Impact factor: 6.998

5.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Authors:  G Gaidano; P Ballerini; J Z Gong; G Inghirami; A Neri; E W Newcomb; I T Magrath; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

6.  Deletions at 11q identify a subset of patients with typical CLL who show consistent disease progression and reduced survival.

Authors:  J R Neilson; R Auer; D White; N Bienz; J J Waters; J A Whittaker; D W Milligan; C D Fegan
Journal:  Leukemia       Date:  1997-11       Impact factor: 11.528

7.  Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes.

Authors:  Dirk L Kienle; Christian Korz; Beate Hosch; Axel Benner; Daniel Mertens; Annett Habermann; Alexander Kröber; Ulrich Jäger; Peter Lichter; Hartmut Döhner; Stephan Stilgenbauer
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

Review 8.  Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis.

Authors:  H Döhner; S Stilgenbauer; K Döhner; M Bentz; P Lichter
Journal:  J Mol Med (Berl)       Date:  1999-02       Impact factor: 4.599

9.  Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia.

Authors:  T Stankovic; P Weber; G Stewart; T Bedenham; J Murray; P J Byrd; P A Moss; A M Taylor
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

Review 10.  Epigenetics in chronic lymphocytic leukemia.

Authors:  Aparna Raval; John C Byrd; Christoph Plass
Journal:  Semin Oncol       Date:  2006-04       Impact factor: 4.929

View more
  2 in total

1.  Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax.

Authors:  Ching Soon Teoh; Ai Sim Goh
Journal:  Case Rep Transplant       Date:  2021-01-22

2.  Cytogenetic Abnormalities with Interphase FISH Method and Clinical Manifestation in Chronic Lymphocytic Leukemia Patients in North-East of Iran.

Authors:  Hossein Rahimi; Mohammad Hadi Sadeghian; Mohammad Reza Keramati; Amir Hossein Jafarian; Sepideh Shakeri; Seyyede Fatemeh Shams; Neda Motamedi; Maryam Sheikhi; Hossein Ayatollahi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2017-07-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.